Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Share-based Compensation (2016 - 2025)

Historic Share-based Compensation for Orthofix Medical (OFIX) over the last 15 years, with Q3 2025 value amounting to $7.2 million.

  • Orthofix Medical's Share-based Compensation rose 995.25% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year increase of 63.96%. This contributed to the annual value of $32.5 million for FY2024, which is 910.75% down from last year.
  • According to the latest figures from Q3 2025, Orthofix Medical's Share-based Compensation is $7.2 million, which was up 995.25% from $7.8 million recorded in Q2 2025.
  • Over the past 5 years, Orthofix Medical's Share-based Compensation peaked at $13.2 million during Q2 2023, and registered a low of $3.2 million during Q4 2023.
  • Over the past 5 years, Orthofix Medical's median Share-based Compensation value was $6.3 million (recorded in 2023), while the average stood at $6.5 million.
  • Examining YoY changes over the last 5 years, Orthofix Medical's Share-based Compensation showed a top increase of 20055.4% in 2023 and a maximum decrease of 3565.62% in 2023.
  • Quarter analysis of 5 years shows Orthofix Medical's Share-based Compensation stood at $4.0 million in 2021, then rose by 24.23% to $4.9 million in 2022, then tumbled by 35.66% to $3.2 million in 2023, then soared by 126.24% to $7.2 million in 2024, then rose by 0.22% to $7.2 million in 2025.
  • Its last three reported values are $7.2 million in Q3 2025, $7.8 million for Q2 2025, and $6.5 million during Q1 2025.